Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites
SYP enhances bevacizumab efficacy by targeting angiogenesis, ferroptosis, and G6PD-mediated resistance, providing a rationale for integrating traditional and modern therapies in HCC management. These findings highlight the value of network pharmacology in elucidating TCM mechanisms and support further clinical evaluation.
Authors
- Zhengxiang Han (ORCID: https://orcid.org/0000-0001-7918-257X)
- Michele Dal Bo (ORCID: https://orcid.org/0000-0001-8668-7621)
- Qingyu Ji (ORCID: https://orcid.org/0000-0002-7963-9936)
- Wulong Wang
- Baiqing Yu (ORCID: https://orcid.org/0000-0002-2765-6558)
- Heyi Li (ORCID: https://orcid.org/0000-0001-6165-9974)
- Kai Li (ORCID: https://orcid.org/0000-0002-6895-0024)
- Jianhua Zhang (ORCID: https://orcid.org/0000-0002-8925-4271)
- Xiaobing Ren (ORCID: https://orcid.org/0000-0002-4973-2486)
- Xiaojie Zhang (ORCID: https://orcid.org/0000-0001-9850-9806)
- Kuiyu You
Institutions
- Inner Mongolia University of Science and Technology (CN)
- Baotou Teachers College (CN)
- Taiwan Centers for Disease Control (TW)
- Baotou Medical College (CN)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1097/ms9.0000000000004420
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52